ABVC BioPharma Inc. is a clinical-stage biopharmaceutical company developing botanical-based therapies for central nervous system, ophthalmology and oncology/hematology indications. ABVC BioPharma Inc. is based in SILICON VALLEY, CA.
| Revenue (Most Recent Fiscal Year) | $0.51M |
| Net Income (Most Recent Fiscal Year) | $-4.90M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 46.71 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.78 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -666.53% |
| Net Margin (Trailing 12 Months) | -963.46% |
| Return on Equity (Trailing 12 Months) | -29.62% |
| Return on Assets (Trailing 12 Months) | -14.08% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.22 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.22 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 0.17 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.47 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.13 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 16.98M |
| Free Float | 14.08M |
| Market Capitalization | $23.77M |
| Average Volume (Last 20 Days) | 0.30M |
| Beta (Past 60 Months) | 0.06 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 17.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 11.38% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |